GT Biopharma (GTBP)
(Delayed Data from NSDQ)
$2.28 USD
+0.14 (6.54%)
Updated Aug 12, 2024 09:45 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GTBP 2.28 +0.14(6.54%)
Will GTBP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GTBP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GTBP
GT Biopharma, Inc. (GTBP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now
GTBP: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy
Has Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
Other News for GTBP
One new option listing and eighteen option delistings on July 22nd
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
GT Biopharma announces FDA clearance of IND application for GTB-3650
GT Biopharma files to sell 740,000 shares of common stock for holders
GT Biopharma files to sell 740,000 shares by holders